Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial

Published:2024-07 Issue:1 Volume:154 Page:179-183
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Petersen Remy S.^ORCID,Fijen Lauré M.,Kelder Johannes P.,Cohn Danny M.^ORCID

Publisher

Elsevier BV

Reference15 articles.

1. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group;Cicardi;Allergy,2014

2. Hereditary angioedema;Busse;N Engl J Med,2020

3. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update;Maurer;World Allergy Organ J,2022

4. Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency;Levi;Allergy,2019

5. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency;Zanichelli;J Allergy Clin Immunol Pract,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP